CY1122456T1 - Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου - Google Patents
Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινουInfo
- Publication number
- CY1122456T1 CY1122456T1 CY20201100008T CY201100008T CY1122456T1 CY 1122456 T1 CY1122456 T1 CY 1122456T1 CY 20201100008 T CY20201100008 T CY 20201100008T CY 201100008 T CY201100008 T CY 201100008T CY 1122456 T1 CY1122456 T1 CY 1122456T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cancer
- monoclonal antibodies
- antibodies
- gdf
- cachesis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1405475.3A GB2524552B (en) | 2014-03-26 | 2014-03-26 | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer |
| GB1405477.9A GB2524553C (en) | 2014-03-26 | 2014-03-26 | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia |
| PCT/EP2015/056654 WO2015144855A1 (en) | 2014-03-26 | 2015-03-26 | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122456T1 true CY1122456T1 (el) | 2021-01-27 |
Family
ID=52745885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100008T CY1122456T1 (el) | 2014-03-26 | 2020-01-08 | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US20170204174A1 (enExample) |
| EP (3) | EP4316596A3 (enExample) |
| JP (3) | JP6865585B2 (enExample) |
| KR (1) | KR102520978B1 (enExample) |
| CN (1) | CN106536553B (enExample) |
| AU (2) | AU2015238264B2 (enExample) |
| BR (1) | BR122023027559A2 (enExample) |
| CY (1) | CY1122456T1 (enExample) |
| DK (2) | DK3122775T3 (enExample) |
| ES (2) | ES2763859T3 (enExample) |
| FI (1) | FI3653644T3 (enExample) |
| HR (2) | HRP20231514T1 (enExample) |
| HU (2) | HUE064573T2 (enExample) |
| IL (2) | IL248038B (enExample) |
| LT (2) | LT3122775T (enExample) |
| NZ (1) | NZ724649A (enExample) |
| PL (2) | PL3122775T3 (enExample) |
| PT (2) | PT3122775T (enExample) |
| RS (1) | RS59700B1 (enExample) |
| SI (1) | SI3122775T1 (enExample) |
| SM (1) | SMT202000064T1 (enExample) |
| WO (1) | WO2015144855A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20231514T1 (hr) | 2014-03-26 | 2024-03-01 | Julius-Maximilians-Universität Würzburg | Monoklonska antitijela za faktor rasta i diferencijacije 15 (gdf-15), te njihova uporaba za liječenje tumorske kaheksije i raka |
| HUE054670T2 (hu) | 2014-09-25 | 2021-09-28 | Aveo Pharmaceuticals Inc | Módszer cachexia visszafordítására és túlélés megnövelésére egy GDF15 modulátor és egy rákellenes szer adagolásával |
| GB201517528D0 (en) * | 2015-10-02 | 2015-11-18 | Julius Maximillians Universitãt Würzburg | GDF-15 as a diagnosis marker for melanoma |
| ES2968226T3 (es) | 2015-10-02 | 2024-05-08 | Univ Wuerzburg J Maximilians | GDF-15 como marcador de diagnóstico para predecir la evolución clínica de un tratamiento con bloqueadores de puntos de control inmunitario |
| US11464856B2 (en) * | 2015-10-02 | 2022-10-11 | Julius-Maximilians-Universität Würzburg | Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers |
| CN109071647B (zh) * | 2016-04-27 | 2022-11-22 | 诺华股份有限公司 | 抗生长分化因子15的抗体及其用途 |
| NZ750244A (en) * | 2016-07-06 | 2025-11-28 | Nat Res Council Canada | Humanized antibodies transmigrating the blood-brain barrier and uses thereof |
| US20190234935A1 (en) * | 2016-10-12 | 2019-08-01 | Janssen Biotech, Inc. | Methods for screening for modulators of gdf15-like biological activity |
| JP7134960B2 (ja) * | 2016-12-06 | 2022-09-12 | セントビンセンツ ホスピタル シドニー リミテッド | 肥満及び摂食障害の治療 |
| JP7155403B2 (ja) * | 2018-08-20 | 2022-10-18 | ファイザー・インク | 抗ｇｄｆ１５抗体、組成物および使用の方法 |
| CA3200687A1 (en) | 2020-11-10 | 2022-05-19 | Catalym Gmbh | Anti-gdf15 antibody and a dosage regimen for the treatment of cancer |
| EP4314071A1 (en) | 2021-03-31 | 2024-02-07 | Cambridge Enterprise Limited | Therapeutic inhibitors of gdf15 signalling |
| AU2022328390A1 (en) | 2021-08-10 | 2024-03-21 | Adimab, Llc | Anti-gdf15 antibodies, compositions and uses thereof |
| US20250382359A1 (en) | 2021-12-22 | 2025-12-18 | Byomass Inc. | Targeting gdf15-gfral pathway |
| US20250092124A1 (en) * | 2022-01-26 | 2025-03-20 | Yunnan Baiyao Group Co., Ltd. | Antibody molecule against growth and differentiation factor 15 and use thereof |
| CN119487065A (zh) | 2022-05-09 | 2025-02-18 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别gdf15的抗体及其应用 |
| CN116462757A (zh) * | 2023-03-24 | 2023-07-21 | 科兴生物制药股份有限公司 | Gdf15的单域抗体及其应用 |
| CN118878677A (zh) * | 2024-09-29 | 2024-11-01 | 江苏凯基生物技术股份有限公司 | 一种IgM亚型单克隆抗体及其制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6455677B1 (en) * | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
| EP0953639A1 (en) * | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
| US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
| EP1179067B1 (en) | 1999-05-17 | 2006-12-13 | BIOPHARM Gesellschaft zur biotechnologischen Entwicklung und zum Vertrieb von Pharmaka mbH | Neuroprotective properties of gdf-15, a member of the tgf-beta superfamily |
| US7141661B2 (en) | 2000-09-08 | 2006-11-28 | The United States Of America As Represented By The Department Of Health And Human Services | Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
| SI1704166T1 (sl) * | 2004-01-07 | 2015-06-30 | Novartis Vaccines And Diagnostics, Inc. | M-scf specifiäśno monoklonsko protitelo in uporabe le-tega |
| CA2561877C (en) | 2004-04-13 | 2017-03-14 | St. Vincent's Hospital Sydney Limited | Use of mic-1 or modulating agent thereof to modulate appetite or body weight |
| US20100278843A1 (en) | 2007-08-16 | 2010-11-04 | St. Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity |
| AU2008310310A1 (en) * | 2007-10-09 | 2009-04-16 | St Vincent's Hospital Sydney Limited | A method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1 |
| JP5581323B2 (ja) | 2008-09-29 | 2014-08-27 | ロシュ グリクアート アクチェンゲゼルシャフト | ヒトｉｌ１７に対する抗体およびその使用 |
| US20120309697A1 (en) | 2009-10-28 | 2012-12-06 | Samuel Norbert Breit | Methods of diagnosing and prognosing colonic polyps |
| US9212221B2 (en) * | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
| KR101398363B1 (ko) * | 2010-11-17 | 2014-05-22 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| CN102321173B (zh) | 2011-08-12 | 2013-04-03 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
| EP2565262A1 (en) | 2011-08-31 | 2013-03-06 | VTU Holding GmbH | Protein expression |
| JP2015506373A (ja) | 2012-01-26 | 2015-03-02 | アムジエン・インコーポレーテツド | 成長分化因子１５（ｇｄｆ−１５）ポリペプチド |
| KR101838786B1 (ko) * | 2012-09-26 | 2018-03-15 | 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 | 성장 및 분화 인자 15 (gdf-15)에 대한 모노클로날 항체 |
| EP2934584B1 (en) | 2012-12-21 | 2020-02-19 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| HRP20231514T1 (hr) | 2014-03-26 | 2024-03-01 | Julius-Maximilians-Universität Würzburg | Monoklonska antitijela za faktor rasta i diferencijacije 15 (gdf-15), te njihova uporaba za liječenje tumorske kaheksije i raka |
-
2015
- 2015-03-26 HR HRP20231514TT patent/HRP20231514T1/hr unknown
- 2015-03-26 JP JP2016559286A patent/JP6865585B2/ja active Active
- 2015-03-26 HR HRP20200034TT patent/HRP20200034T1/hr unknown
- 2015-03-26 CN CN201580027932.8A patent/CN106536553B/zh active Active
- 2015-03-26 RS RS20191652A patent/RS59700B1/sr unknown
- 2015-03-26 EP EP23203704.4A patent/EP4316596A3/en active Pending
- 2015-03-26 DK DK15712629.3T patent/DK3122775T3/da active
- 2015-03-26 KR KR1020167029710A patent/KR102520978B1/ko active Active
- 2015-03-26 EP EP15712629.3A patent/EP3122775B1/en active Active
- 2015-03-26 SM SM20200064T patent/SMT202000064T1/it unknown
- 2015-03-26 AU AU2015238264A patent/AU2015238264B2/en active Active
- 2015-03-26 EP EP19205321.3A patent/EP3653644B1/en active Active
- 2015-03-26 PT PT157126293T patent/PT3122775T/pt unknown
- 2015-03-26 PL PL15712629T patent/PL3122775T3/pl unknown
- 2015-03-26 FI FIEP19205321.3T patent/FI3653644T3/fi active
- 2015-03-26 ES ES15712629T patent/ES2763859T3/es active Active
- 2015-03-26 NZ NZ724649A patent/NZ724649A/en unknown
- 2015-03-26 SI SI201531059T patent/SI3122775T1/sl unknown
- 2015-03-26 HU HUE19205321A patent/HUE064573T2/hu unknown
- 2015-03-26 US US15/128,604 patent/US20170204174A1/en not_active Abandoned
- 2015-03-26 WO PCT/EP2015/056654 patent/WO2015144855A1/en not_active Ceased
- 2015-03-26 PT PT192053213T patent/PT3653644T/pt unknown
- 2015-03-26 LT LTEP15712629.3T patent/LT3122775T/lt unknown
- 2015-03-26 BR BR122023027559-4A patent/BR122023027559A2/pt not_active Application Discontinuation
- 2015-03-26 DK DK19205321.3T patent/DK3653644T5/da active
- 2015-03-26 LT LTEP19205321.3T patent/LT3653644T/lt unknown
- 2015-03-26 PL PL19205321.3T patent/PL3653644T3/pl unknown
- 2015-03-26 ES ES19205321T patent/ES2965626T3/es active Active
- 2015-03-26 HU HUE15712629A patent/HUE047398T2/hu unknown
-
2016
- 2016-09-26 IL IL248038A patent/IL248038B/en active IP Right Grant
-
2018
- 2018-03-05 US US15/912,358 patent/US10604565B2/en active Active
-
2020
- 2020-01-08 CY CY20201100008T patent/CY1122456T1/el unknown
- 2020-02-19 US US16/794,401 patent/US11634482B2/en active Active
- 2020-02-19 US US16/794,406 patent/US11760795B2/en active Active
- 2020-07-30 IL IL276405A patent/IL276405B/en unknown
- 2020-10-28 AU AU2020260440A patent/AU2020260440B2/en active Active
-
2021
- 2021-04-06 JP JP2021064572A patent/JP7607498B2/ja active Active
-
2023
- 2023-04-06 JP JP2023062338A patent/JP2023098966A/ja not_active Withdrawn
- 2023-08-02 US US18/364,173 patent/US20230382987A1/en not_active Abandoned
-
2025
- 2025-06-13 US US19/237,241 patent/US20260008841A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
| CY1123977T1 (el) | Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| CY1121832T1 (el) | Μονοκλωνικα αντισωματα κατα του παραγοντα αναπτυξεως και διαφοροποιησεως 15(gdf-15) | |
| CO2017004516A2 (es) | Anticuerpos anti-ox40 humanizados | |
| MX2022014914A (es) | Compuestos de interaccion con glicanos y metodos de uso. | |
| PH12020552229A1 (en) | Il-11ra antibodies | |
| EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
| CY1119445T1 (el) | Αντισωματα εναντι του ανθρωπινου gdf8 | |
| EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| MX2023005881A (es) | Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso. | |
| MX385853B (es) | Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr. | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| AR103726A1 (es) | Cristales de anticuerpos monoclonales anti-pd-1 humanos | |
| MX2016012094A (es) | Composiciones de anticuerpos para tratamiento tumoral. | |
| EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
| MX2020007406A (es) | Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. | |
| MY175878A (en) | Anti-il-17 antibodies, a method for producing and using thereof | |
| EP4603508A3 (en) | Anti-frizzled antibodies and methods of use | |
| CY1125400T1 (el) | Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων | |
| UA118354C2 (uk) | Антитіло до рецептора колонієстимулювального фактора (кфс-1r) | |
| EA201990894A1 (ru) | Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения | |
| EA202191769A1 (ru) | Тубулизины и конъюгаты белок-тубулизин | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. |